1Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126(3 Suppl): 338-400.
2Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): 9-16.
3Liew NC, Moissinac K, Gul Y. Postoperative venous thromboembolism in Asia: a critical appraisal of its incidence. Asian J Surg,2003, 26: 154-158.
4Geerts WH, Heir JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest, 2001, 119(1 Suppl): 132-175.
5Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med, 2002, 162: 1833-1840.
6Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg(Am), 2001, 83: 900-906.
7Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest, 2003, 124(6 Suppl): 386-392.
8O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med, 2003, 163:1362-1366.
9Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of lowmolecular-weight heparin with oral anticoagulant. Arch Intern Med,2002, 162: 2191-2196.
10AIDA: 45th American Society of Hematology Annual Meeting. San Diego, 2003.
4Heit JA, O' Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med,2002,162 ( 11 ) : 1245- 1248.
5Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation,2003,107 (23 Suppl 1 ) : 19-116.
